Back to Journals » Drug Design, Development and Therapy » Volume 5
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Published 16 December 2011 Volume 2011:5 Pages 489—495
DOI https://doi.org/10.2147/DDDT.S10945
Review by Single anonymous peer review
Peer reviewer comments 2
Sapna P Patel, Scott E Woodman
Melanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Abstract: Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.
Keywords: ipilimumab, melanoma, T-cells, CTLA-4
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.